EUVIMEDDescoperă EUVIMED
Open access · CC BY 4.0

Evaluation of Anti-VEGFR2 Specific Photoimmunotherapy for Targeted Regression of Neovascularization in an AMD Model

Hideto Osada, Takashi Nishimura, Makoto Mitsunaga, Masayuki Saruta, Kazuo Tsubota, Kazuno Negishi, Toshihide Kurihara, Norimitsu Ban

Investigative Ophthalmology & Visual Science · 2025

DOI: 10.1167/iovs.66.6.70 ↗

At a glance

Journal article in Investigative Ophthalmology & Visual Science, 2025. Written by Hideto Osada and 7 co-authors. Institution: Laboratory of Aging and Retinal Biology, Keio University School of Medicine, Tokyo, Japan. Major MEDLINE topics: Vascular Endothelial Growth Factor Receptor-2, Choroidal Neovascularization, Photosensitizing Agents, Immunotherapy. Cited 2 times so far (Crossref); 32 references. The full text is freely available (open access, CC BY 4.0).

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Purpose

This study aimed to evaluate the efficacy of photoimmunotherapy (PIT) targeting VEGFR2 for the treatment of neovascular AMD and to investigate its potential as a novel therapeutic strategy.

Methods

DC101-IR700, a conjugate of the anti-mouse VEGFR2 monoclonal antibody DC101 and the photosensitizer IR700, was investigated both in vitro and in vivo. VEGFR2 expression in endothelial cells was confirmed via qPCR and immunocytochemistry. Laser-induced choroidal neovascularization (CNV) was established in C57BL/6J mice. Localization of DC101-IR700 within CNV lesions was assessed by immunofluorescence. After PIT was performed using either a 690 nm near-infrared manual laser or a slit lamp laser, CNV volumes were quantified through confocal microscopy. Cell viability post PIT was measured using MTT assay and cell death in CNV lesions was evaluated using TUNEL staining.

Results

DC101-IR700 localized specifically to VEGFR2-positive cells in CNV lesions, and PIT induced significant VEGFR2-dependent cytotoxicity in vitro. In vivo, both PIT and directional PIT using slit lamp laser significantly reduced CNV volumes compared with controls. TUNEL staining confirmed VEGFR2-specific cell death in treated CNV lesions. Directional PIT achieved similar efficacy to PIT, demonstrating its potential as a clinically viable alternative.

Conclusions

PIT targeting VEGFR2 selectively induced cell death in pathological neovascular tissues, significantly reducing CNV volume in an AMD model. These findings suggest that VEGFR2-specific PIT represents a promising and targeted approach for treating neovascular AMD, offering advantages over conventional anti-VEGF therapies by potentially decreasing treatment frequency and improving efficacy.

Subjects

MeSH terms (MEDLINE)

Vascular Endothelial Growth Factor Receptor-2Choroidal NeovascularizationPhotosensitizing AgentsImmunotherapyAntibodies, MonoclonalAnimalsMiceDisease Models, AnimalMice, Inbred C57BLMicroscopy, ConfocalIn Situ Nick-End LabelingHumansPhotochemotherapy

Substances

Vascular Endothelial Growth Factor Receptor-2Photosensitizing AgentsAntibodies, MonoclonalDC101 monoclonal antibodyKdr protein, mouse

Authors and institutions

  • Laboratory of Aging and Retinal Biology, Keio University School of Medicine, Tokyo, Japan.
  • Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
  • Tsubota Laboratory, Inc., Tokyo, Japan.
  • Laboratory of Photobiology, Keio University School of Medicine, Tokyo, Japan.

Cite

APA

Osada, H., Nishimura, T., Mitsunaga, M., Saruta, M., Tsubota, K., Negishi, K., Kurihara, T., & Ban, N. (2025). Evaluation of Anti-VEGFR2 Specific Photoimmunotherapy for Targeted Regression of Neovascularization in an AMD Model. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.66.6.70

Vancouver

Osada H, Nishimura T, Mitsunaga M, Saruta M, Tsubota K, Negishi K, et al. Evaluation of Anti-VEGFR2 Specific Photoimmunotherapy for Targeted Regression of Neovascularization in an AMD Model. Investigative Ophthalmology & Visual Science. 2025. doi:10.1167/iovs.66.6.70

BibTeX
@article{Osada2025,
  author = {Osada, Hideto and Nishimura, Takashi and Mitsunaga, Makoto and Saruta, Masayuki and Tsubota, Kazuo and Negishi, Kazuno and Kurihara, Toshihide and Ban, Norimitsu},
  title = {Evaluation of Anti-VEGFR2 Specific Photoimmunotherapy for Targeted Regression of Neovascularization in an AMD Model},
  journal = {Investigative Ophthalmology & Visual Science},
  year = {2025},
  doi = {10.1167/iovs.66.6.70}
}
Start for free →